SPHS Sophiris Bio Inc.

+0.02  (+2%)
Previous Close 1
Open 0.98
Price To Book -12.75
Market Cap 30,821,483
Shares 30,217,140
Volume 42,815
Short Ratio
Av. Daily Volume 162,365

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial dependent on funding.
Topsalysin (PRX302)
Localized low to intermediate risk prostate cancer
Phase 3 primary endpoints met - November 2015. Second Phase 3 trial dependent on funding.
Topsalysin (PRX302)
Benign prostatic hyperplasia

Latest News

  1. Sophiris Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
  2. SPHS: Details of Phase 3 Prostate Cancer Trial Based on Positive EMA Feedback…
  3. Sophiris Bio Receives Positive Feedback from European Medicines Agency Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design
  4. Some Sophiris Bio (FRA:BFF1) Shareholders Have Taken A Painful 79% Share Price Drop
  5. SPHS: EMA Guidance on Phase 3 Clinical Trial for Topsalysin Expected in 2Q19…
  6. Sophiris Bio Reports First Quarter 2019 Financial Results
  7. Sophiris Bio to Present at Two Upcoming Investor Conferences
  8. SPHS: Awaiting Regulatory Guidance for Topsalysin Phase 3 Study…
  9. Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights
  10. SPHS: Ready to Move Topsalysin into Phase 3 for Localized Clinically Significant Prostate Cancer…
  11. Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial
  12. Does Sophiris Bio Inc (FRA:BFF1) Have A Volatile Share Price?
  13. SPHS: Data from Second Administration of Topsalysin in Phase 2b Trial Anticipated Before End of 2018…
  14. Report: Exploring Fundamental Drivers Behind HC2, Pangaea Logistics Solutions, Sophiris Bio, Acacia Research, JAKKS Pacific, and LeMaitre Vascular — New Horizons, Emerging Trends, and Upcoming Developments
  15. Sophiris Bio to Present at the Piper Jaffray Healthcare Conference
  16. Sophiris Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
  17. Sophiris Bio to Present at the Cantor Global Healthcare Conference
  18. Sophiris Bio Extends the Interest Only Period under its Loan and Security Agreement
  19. SPHS: Patient Death in Phase 2b Trial Unlikely Related to Topsalysin Treatment…
  20. Today’s Research Reports on Stocks to Watch: Opiant Pharmaceuticals and Sophiris Bio